Switzerland: Market for Other Medicaments For Therapeutic Or Prophylactic Uses 2024

Market Size for Other Medicaments For Therapeutic Or Prophylactic Uses in Switzerland

The Swiss market for other medicaments for therapeutic or prophylactic uses reduced markedly to $X in 2022, with a decrease of X% against the previous year. Over the period under review, consumption recorded a slight setback. As a result, consumption reached the peak level of $X. From 2020 to 2022, the growth of the market remained at a lower figure.

Production of Other Medicaments For Therapeutic Or Prophylactic Uses in Switzerland

In value terms, production of other medicaments for therapeutic or prophylactic uses fell slightly to $X in 2022 estimated in export price. Over the period under review, the total production indicated prominent growth from 2012 to 2022: its value increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production decreased by X% against 2019 indices. The pace of growth appeared the most rapid in 2019 when the production volume increased by X% against the previous year. As a result, production reached the peak level of $X. From 2020 to 2022, production of growth failed to regain momentum.

Exports of Other Medicaments For Therapeutic Or Prophylactic Uses

Exports from Switzerland

In 2022, the amount of other medicaments for therapeutic or prophylactic uses exported from Switzerland expanded rapidly to X tons, growing by X% against the year before. Overall, total exports indicated a prominent increase from 2012 to 2022: its volume increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, exports increased by X% against 2019 indices. The pace of growth appeared the most rapid in 2020 when exports increased by X% against the previous year. The exports peaked in 2022 and are expected to retain growth in the near future.

In value terms, exports of other medicaments for therapeutic or prophylactic uses soared to $X in 2022. Over the period under review, exports saw strong growth. The pace of growth appeared the most rapid in 2018 with an increase of X% against the previous year. Over the period under review, the exports of hit record highs in 2022 and are likely to see steady growth in the immediate term.

Exports by Country

Germany (X tons), China (X tons) and Spain (X tons) were the main destinations of exports of other medicaments for therapeutic or prophylactic uses from Switzerland, together comprising X% of total exports. Japan, Estonia, Egypt, Turkey, Italy, Austria, the Netherlands, the UK, Saudi Arabia and France lagged somewhat behind, together accounting for a further X%.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by Estonia (with a CAGR of X%), while the other leaders experienced more modest paces of growth.

In value terms, Spain ($X) remains the key foreign market for other medicaments for therapeutic or prophylactic uses exports from Switzerland, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports. It was followed by Italy, with an X% share.

From 2012 to 2022, the average annual growth rate of value to Spain stood at X%. Exports to the other major destinations recorded the following average annual rates of exports growth: China (X% per year) and Italy (X% per year).

Export Prices by Country

The average export price for other medicaments for therapeutic or prophylactic uses stood at $X per ton in 2022, with an increase of X% against the previous year. In general, the export price continues to indicate pronounced growth. The most prominent rate of growth was recorded in 2018 when the average export price increased by X% against the previous year. The export price peaked at $X per ton in 2019; however, from 2020 to 2022, the export prices remained at a lower figure.

There were significant differences in the average prices for the major external markets. In 2022, amid the top suppliers, the country with the highest price was Spain ($X,505 per ton), while the average price for exports to Germany ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to Austria (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Other Medicaments For Therapeutic Or Prophylactic Uses

Imports into Switzerland

Imports of other medicaments for therapeutic or prophylactic uses into Switzerland declined to X tons in 2022, waning by X% on 2021. In general, imports, however, recorded a modest increase. The most prominent rate of growth was recorded in 2020 with an increase of X% against the previous year. As a result, imports reached the peak of X tons. From 2021 to 2022, the growth of imports of remained at a lower figure.

In value terms, imports of other medicaments for therapeutic or prophylactic uses declined notably to $X in 2022. Over the period under review, imports, however, continue to indicate mild growth. The pace of growth was the most pronounced in 2016 with an increase of X%. Over the period under review, imports of attained the peak figure at $X in 2018; however, from 2019 to 2022, imports failed to regain momentum.

Imports by Country

Germany (X tons), France (X tons) and the United States (X tons) were the main suppliers of imports of other medicaments for therapeutic or prophylactic uses to Switzerland, together accounting for X% of total imports. Slovenia, Italy, China, Austria and the Netherlands lagged somewhat behind, together accounting for a further X%.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main suppliers, was attained by China (with a CAGR of X%), while imports for the other leaders experienced more modest paces of growth.

In value terms, the largest other medicaments for therapeutic or prophylactic uses suppliers to Switzerland were Germany ($X), Italy ($X) and Slovenia ($X), together comprising X% of total imports. The United States, France, Austria, China and the Netherlands lagged somewhat behind, together comprising a further X%.

China, with a CAGR of X%, saw the highest growth rate of the value of imports, among the main suppliers over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

In 2022, the average import price for other medicaments for therapeutic or prophylactic uses amounted to $X per ton, declining by X% against the previous year. Over the period under review, the import price, however, recorded a relatively flat trend pattern. The pace of growth was the most pronounced in 2017 when the average import price increased by X%. Over the period under review, average import prices attained the peak figure at $X per ton in 2018; however, from 2019 to 2022, import prices remained at a lower figure.

Prices varied noticeably by country of origin: amid the top importers, the country with the highest price was Italy ($X per ton), while the price for France ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by the Netherlands (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :